Breast cancer survival in the US and Europe: A CONCORD high-resolution study

International Journal of Cancer

Volumn 132, Issue 5, 2013, Pages 1170-1181

  Allemani, Claudia ^a,b   Sant, Milena ^b   Weir, Hannah K ^c   Richardson, Lisa C ^c   Baili, Paolo ^b   Storm, Hans ^d   Siesling, Sabine ^e   Torrella Ramos, Ana ^f   Voogd, Adri C ^f   Aareleid, Tiiu ^g   Ardanaz, Eva ^h   Berrino, Franco ^b   Bielska Lasota, Magdalena ⁱ   Bolick, Susan ^j   Cirilli, Claudia ^k   Colonna, Marc ^f   Contiero, Paolo ^b   Cress, Rosemary ^l   Crocetti, Emanuele ^m   Fulton, John P ⁿ   Grosclaude, Pascale ^o   Hakulinen, Timo ^p   Izarzugaza, M Isabel ^q   Malmström, Per ^r   Peignaux, Karin ^s   Primic Žakelj, Maja ^t   Rachtan, Jadwiga ^u   Safaei Diba, Chakameh ^v   Sánchez, Maria José ^w   Schymura, Maria J ^x   Shen, Tiefu ^y   Traina, Adele ^z   Tryggvadottir, Laufey ^aa,ab   Tumino, Rosario ^ac   Velten, Michel ^ad   Vercelli, Marina ^ae,af   Wolf, Holly J ^ag   Woronoff, Anne Sophie ^ah   Wu, Xiaocheng ^ai   Coleman, Michel P ^a   more..

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^e Netherlands Comprehensive Cancer Organisation   (Netherlands)

^f Cancer Registry Castellón ^*  (France)

^g NATIONAL INSTITUTE FOR HEALTH DEVELOPMENT   (Estonia)

^h INSTITUTO DE SALUD PÚBLICA DE NAVARRA   (Spain)

ⁱ NATIONAL INSTITUTE OF HYGIENE   (Poland)

^j South Carolina Central Cancer Registry   (United States)

^k MODENA CANCER REGISTRY   (Italy)

^l PUBLIC HEALTH INSTITUTE   (United States)

^m ISPO   (Italy)

ⁿ Rhode Island Vascular Institute   (United States)

^o Tarn Cancer Registry   (France)

^p FINNISH CANCER REGISTRY   (Finland)

^q Scio de Registros e Información Sanitaria   (Spain)

^r LUND UNIVERSITY HOSPITAL   (Sweden)

^s CENTRE GEORGES FRANÇOIS LECLERC   (France)

^t INSTITUTE OF ONCOLOGY   (Slovenia)

^u INSTITUTE OF ONCOLOGY   (Poland)

^v CANCER RESEARCH INSTITUTE   (Slovakia)

^w ANDALUSIAN SCHOOL OF PUBLIC HEALTH   (Spain)

^x New York State Cancer Registry   (United States)

^y Illinois State Cancer Registry   (United States)

^z ARNAS Civico   (Italy)

^aa UNIVERSITY OF ICELAND   (Iceland)

^ab ICELANDIC CANCER REGISTRY   (Iceland)

^ac Civile MP Arezzo Hospital   (Italy)

^ad UNIVERSITÉ DE STRASBOURG   (France)

^ae CENTRO DI BIOTECNOLOGIE AVANZATE   (Italy)

^af UNIVERSITY OF GENOA   (Italy)

^ag Global Health and Health Disparities   (United States)

^ah UNIVERSITY HOSPITAL OF BESANÇON   (France)

^ai LSUHSC School of Public Health   (United States)

more..

Author keywords

cancer registries; CONCORD; excess hazard; net survival

Indexed keywords

ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; ADVANCED CANCER; AGE; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CONTROLLED STUDY; EUROPE; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; POPULATION RESEARCH; PRIORITY JOURNAL; UNITED STATES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; EUROPE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; REGISTRIES; UNITED STATES; YOUNG ADULT;

EID: 84872849005     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27725     Document Type: Article

References (30)

1. Cutler SJ, ed. International symposium on end results of cancer therapy. NCI Monograph 15. Bethesda MD: National Cancer Institute, 1964.
2. Gatta G, Capocaccia R, Coleman MP, et al. Toward a comparison of survival in American and European cancer patients. Cancer 2000; 89: 893-900.
3. Coleman MP, Quaresma M, Berrino F, et al. Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol 2008; 9: 730-56.
4. Sant M, Allemani C, Berrino F, et al. Breast carcinoma survival in Europe and the USA: a population-based study. Cancer 2004; 100: 715-22.
5. Sant M, EUROCARE Working Group. Differences in stage and therapy for breast cancer across Europe. Int J Cancer 2001; 93: 894-901.
6. Allemani C, Storm H, Voogd AC, et al. Variation in 'standard care' for breast cancer across Europe: a EUROCARE-3 high resolution study. Eur J Cancer 2010; 46: 1528-36.
7. Sariego J,. Regional variation in breast cancer treatment throughout the United States. Am J Surg 2008; 196: 572-4.
8. Wu X, Richardson LC, Kahn AR, et al. Survival difference between non-Hispanic black and non-Hispanic white women with localized breast cancer: the impact of guideline-concordant therapy. J Natl Med Assoc 2008; 100: 490-8.
9. Lazovich D, Solomon CC, Thomas DB, et al. Breast conservation therapy in the United States following the 1990 National Institutes of Health consensus development conference on the treatment of patients with early-stage invasive breast carcinoma. Cancer 1999; 86: 628-37.
10. Nattinger AB, Hoffmann RG, Kneusel RT, et al. Relation between the appropriateness of primary therapy for early-stage breast carcinoma and increased use of breast-conserving surgery. Lancet 2000; 356: 1148-53.
11. Sant M, Allemani C, Santaquilani M, et al. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999: results and commentary. Eur J Cancer 2009; 45 (Suppl. 6): 931-91.
12. Spiessl B, Beahrs OH, Hermanek P, et al., eds. TNM Atlas: illustrated guide to the TNM/pTNM classification of malignant tumors. Berlin: Springer Verlag, 1992.
13. Nelson CP, Lambert PC, Squire IB, et al. Flexible parametric models for relative survival, with application in coronary heart disease. Stat Med 2007; 26: 5486-98.
14. Estève J, Benhamou E, Raymond L,. Statistical methods in cancer research, vol. 4. Descriptive epidemiology. (IARC Scientific Publications No. 128). Lyon: International Agency for Research on Cancer, 1994.
15. Pohar Perme M, Stare J, Estève J,. On estimation in relative survival. Biometrics 2012; 68: 113-120.
16. Baili P, Micheli A, De Angelis R, et al. Life-tables for world-wide comparison of relative survival for cancer (CONCORD study). Tumori 2008; 94: 658-68.
17. Akaike H,. A new look at the statistical model identification. IEEE Trans Automatic Control 1974; 19: 716-23.
18. Lambert PC, Royston P,. Further development of flexible parametric models for survival analysis. Stata J 2009; 9: 265-90.
19. Danieli C, Remontet L, Bossard N, Roche L, Belot A,. Estimating net survival: the importance of allowing for informative censoring. Stat Med 2012; 31: 775-786.
20. Corazziari I, Quinn MJ, Capocaccia R,. Standard cancer patient population for age standardising survival ratios. Eur J Cancer 2004; 40: 2307-16.
21. National Cancer Institute. SEER Stat-cancer incidence public use database 1973-95. Bethesda, MD: National Cancer Institute, version 1.1, 1998.
22. Merrill RM, Dearden KA,. How representative are the surveillance, epidemiology, and end results (SEER) Program cancer data of the United States? Cancer Causes Control 2004; 15: 1027-34.
23. Christensen LH, Engholm G, Cortes R, et al. Reduced mortality for women with mammography-detected breast cancer in east Denmark and south Sweden. Eur J Cancer 2006; 42: 2773-80.
24. Alley LG, Chen VW, Wike JM, et al. CDC and NPCR's breast, colon, and prostate cancer data quality and patterns of care study: overview and methodology. J Registry Manag 2007; 34: 148-57.
25. Nattinger AB, Kneusel RT, Hoffmann RG, et al. Relationship of distance from radiotherapy facility and initial breast cancer treatment. J Natl Cancer Inst 2001; 93: 1344-6.
26. Tange UB, Jensen MB, Vejborg IM, et al. Clinical impact of introduction of mammography screening in a non-screening country with special reference to the Copenhagen service mammography screening programme. Scand J Surg 2002; 91: 293-303.
27. Anonymous. Update of the NCCN guidelines for treatment of breast cancer. Oncology 1997; 11: 199-220.
28. Anonymous. Consensus conference: adjuvant chemotherapy for breast cancer. J Am Med Assoc 1985; 254: 3461-3.
29. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 1992; 339: 1-15, 71-85.
30. Early Breast Cancer Trialists' Collaborative Group,. Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet 1998; 352: 930-42.